MUC16 and ovarian serous adenocarcinoma: The in vitro and in vivo models are consistent with the adverse effects of MUC16 expression levels in serous ovarian cancer and promote the understanding of MUC16 as a pathogenic contributor to the behaviors of ovarian cancer.